David Solomon was under siege from partners critical of his leadership. The firm launched a probe to identify leakers.

Goldman Sachs' Denis Coleman and Morgan Stanley's Lauren Belmonte on how sweating the small stuff can boost your career.

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as ...

Goldman Sachs analyst David Roman initiated coverage with a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $104.00. The company’s shares closed ...

Goldman Sachs initiated coverage of DexCom (DXCM) stock with a Buy rating and a price target of $104 as part of a broader research note commencing coverage on Diabetes Medical Technology. Goldman ...

DexCom, a global leader in glucose biosensing systems, stands out for its innovative continuous glucose monitoring (CGM) ...

Shares of Beta Bionics rose Thursday following the initiation of coverage by two Wall Street financial firms on the ...